anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Complication mitigation in deep brain stimulation has been a topic matter of much discussion in the literature. In this article, we examine how neurosurgeons as individuals and as a field generated and adapted techniques to prevent infection, lead fracture/lead migration, and suboptimal outcomes in both the acute period and longitudinally. The authors performed a MEDLINE search inclusive of articles from 1987 to June 2023 including human studies written in English. Using the Rayyan platform, two reviewers (J.P. and R.M.) performed a title screen. Of the 776 articles, 252 were selected by title screen and 172 from abstract review for full-text evaluation. Ultimately, 124 publications were evaluated. We describe the initial complications and inefficiencies at the advent of deep brain stimulation and detail changes instituted by surgeons that reduced them. Furthermore, we discuss the trend in both undesired short-term and long-term outcomes with emphasis on how surgeons recognized and modified their practice to provide safer and better procedures. This scoping review adds to the literature as a guide to both new neurosurgeons and seasoned neurosurgeons alike to understand better what innovations have been trialed over time as we embark on novel targets and neuromodulatory technologies.
Described is a process for the preparation of a stable dispersion of solid particles, in an aqueous medium comprising combining (a) a first solution comprising a substantially water-insoluble substance, a water-miscible organic solvent and an inhibitor with (b) an aqueous phase comprising water and optionally a stabiliser, thereby precipitating solid particles comprising the inhibitor and the substantially water-insoluble substance; and optionally removing the water-miscible organic solvent; wherein the inhibitor is a non-polymeric hydrophobic organic compound as defined in the description. The process provides a dispersion of solid particles in an aqueous medium, which particles exhibit reduced or substantially no particle growth mediated by Ostwald ripening. Figure 1 is a graph of the (mean particle diameter)3 (nm3) against time (minutes) for particles of felodipine prepared with and without the use of an inhibitor (Miglyol 812N). The open circles in figure 1 represent the felodipine particles prepared with the inhibitor (Miglyol 812N) and the solid circles felodipine particles prepared without an inhibitor. Figure 1 shows that the presence of the inhibitor eliminated Ostwald ripening in the felodipine particles and the particle size remains constant. Whereas the felodipine particles prepared without an inhibitor grew rapidly with time.
A research team of Centre Henri Becquerel recently detected an unexpected recurrent point mutation of XPO1 (exportin 1) (also known as Chromosome Region Maintenance 1) located in exon 15 (c.1711G\>A) leading to the Glu571Lys (p.E571K) missense substitution in relapsed/refractory (R/R) Primary Mediastinal Large B-cell Lymphoma (PMBL) patients included in the LYSA LNH03 trial program and in classical Hodgkin's Lymphoma patients. It was found recurrent XPO1 E571K mutations in a large cohort of 94 patients with classical Hodgkin's lymphoma. This observation is new and could add new information on driver events and tumorigenesis in this disease. In total, 24.2 % of the patients with classical Hodgkin's lymphoma harbored the XPO1 E571K mutation. It is remarkable that 29% of all XPO1 mutations were only found in the plasma but not in the tumor because of the well-known tumor cell sparsity in Hodgkin's lymphoma. In this particular disease, highly sensitive techniques like digital Polymerase Chain Reaction and targeted Next-Generation Sequencing are essential to highlight low frequency mutations. The research team of the Centre Henri Becquerel have identified a trend toward unfavorable prognostic impact in terms of progression-free survival in patients with detectable XPO1 E571K mutation in plasma cell-free DNA at the end of treatment, which could prove to be statistically significant in a larger cohort. It was observed that 57% of patients who ultimately relapsed were positive in the plasma after end of therapy. It remains to be established whether this mutation adds new relevant value as compared to Positron Emission Tomography-scan.
PURPOSE: A cosmetic composition containing a physiologically acceptable medium and a compound giving a melting peak with a mid-height width of 20deg.C or less is provided. It has thermal stability and can deposit the film having improved curling characteristics on keratin fiber and be used by the combination with a heating device such as a heating brush. CONSTITUTION: The cosmetic composition having thermal stability consists of: a physiologically acceptable medium; and 1 to 60% by weight of at least one compound giving a thermal profile having a melting peak of a mid-height width Lf of 20deg.C or less to the composition. The compound is selected from wax, a polymer such as a semi-crystalline polymer, oil thickened with a structuring agent and a mixture thereof. The semi-crystalline polymer is selected from at least one monomer and copolymers formed by polymerization of at least one fluorinated or not fluorinated C1-10 monocarboxylic acid ester or amide of the formula 1. In formula, R1 is H or CH3, R is fluorinated or not fluorinated C1-10 alkyl, X is O, NH or NR2(R2 is fluorinated or not fluorinated C1-10 alkyl).
PURPOSE: Heterozygous STAT1 Gain-of-Function (GOF) mutations are the most common cause of chronic mucocutaneous candidiasis (CMC) among Inborn Errors of Immunity. Clinically, these mutations manifest as a broad spectrum of immune dysregulation, including autoimmune diseases, vascular disorders, and malignancies. The pathogenic mechanisms of immune dysregulation and its impact on immune cells are not yet fully understood. In treatment, JAK inhibitors have shown therapeutic effectiveness in some patients.
METHODS: We analyzed clinical presentations, cellular phenotypes, and functional impacts in five Taiwanese patients with STAT1 GOF.
RESULTS: We identified two novel GOF mutations in 5 patients from 2 Taiwanese families, presenting with symptoms of CMC, late-onset rosacea, and autoimmunity. The enhanced phosphorylation and delayed dephosphorylation were displayed by the patients' cells. There are alterations in both innate and adaptive immune cells, including expansion of CD38+HLADR +CD8+ T cells, a skewed activated Tfh cells toward Th1, reduction of memory, marginal zone and anergic B cells, all main functional dendritic cell lineages, and a reduction in classical monocyte. Baricitinib showed therapeutic effectiveness without side effects.
CONCLUSION: Our study provides the first comprehensive clinical and molecular characteristics in STAT1 GOF patient in Taiwan and highlights the dysregulated T and B cells subsets which may hinge the autoimmunity in STAT1 GOF patients. It also demonstrated the therapeutic safety and efficacy of baricitinib in pediatric patient. Further research is needed to delineate how the aberrant STAT1 signaling lead to the changes in cellular populations as well as to better link to the clinical manifestations of the disease.
The invention discloses a specific short peptide, a recombinant mesenchymal stem cell expressing the specific short peptide and application of the specific short peptide and the recombinant mesenchymal stem cell. The invention protects a polypeptide, which is shown as a sequence 1 in a sequence table. Nucleic acid molecules encoding such polypeptides are also within the scope of the invention. The invention also protects recombinant mesenchymal stem cells expressing the polypeptide. The invention also protects a product, the active ingredient of which is any one of the recombinant mesenchymal stem cells; the product is used for treating autoimmune diseases. The invention has great application value for treating autoimmune diseases.
Rhinosinusitis (RS) is a heterogenous disease, with variable etiologies, manifestations, and progression. Generally, RS can be divided into acute, subacute, and chronic RS, depending on the symptoms and duration of the disease. Most commonly, acute RS is caused by a viral infection (viral RS), which starts in the nasal passages and progresses to inflammation of the sinuses. When this inflammation of the paranasal sinuses does not resolve and lasts for at least 12 weeks, the disorder is broadly defined as chronic RS (CRS), which is usually accompanied by bacterial infections. This inflammatory disease pathophysiology is further subdivided into CRS with (CRSwNP) and without (CRSsNP) nasal polyps. Recently, several studies aimed at phenotyping the diverse pathophysiology among patients suffering from CRS characterized subgroups based on the presence of inflammatory clusters. CRSsNP is marked by pro-inflammatory neutrophilic inflammation of the nasal mucosa and a nasal cytokine profile that is characterized by increased levels of TGFβ1 and IFNγ and low or undetectable levels of IL-5. In contrast, patients with CRSwNP demonstrate eosinophilic inflammation of the nasal mucosa, low levels of TGFβ1, but high levels of Th2/Th17-type cytokines such as IL-17 and IL-5, higher levels of eosinophil cationic protein (ECP) and mast cell tryptase, and lower levels of IL-10.

Currently biomarkers associated with physician diagnosed disease severity and patient-perceived quality of life impairments are lacking. Analysis of markers of inflammation in the nasal mucosa and peripheral blood leukocytes in combination with quality of life symptom scoring will enable us to identify biomarkers associated with CRS disease severity. This study will determine if biomarkers identified in the nasal mucosa and peripheral blood leukocytes correlate with physician diagnosed and patient-perceived disease severity.
Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
It is a multi-arm parallel Randomized Controlled Trial in which forty patients aged between 4 to 8 years, each containing at-least one non-vital primary molar, will be selected and randomly divided into Group A (Formocresol) and Group B (Allium sativum oil). Non-vital Pulpotomy will be performed by removing the coronal necrotic pulp. Sterile paper point will be dipped in the root canals and taken to the laboratory. Cotton pellets soaked in the respective medicaments will be placed over the root canal orifices and filled temporarily. Patients will be recalled after one week. Samples will be again taken, and tooth restored. Comparison between bacterial count at baseline and after one week of treatment will be made and expressed as Colony-Forming Units/ml (CFU/ml).
The present invention belongs to the field of aquatic product processing technology. Fresh water fish and leftover as material is processed into three kinds of product including crisp fish fillet, anti-fatigue amino acid oral liquid and pet food. Thin fish sheet is produced into crisp fish fillet through soaking in red tea and NaCl solution to eliminate fishy smell, drying, pickling to season, beating to loosen and soften and microwave embrittling. Fish leftover is produced into anti-fatigue amino acid oral liquid through enzymolysis with composite enzyme, killing enzyme, high speed centrifugating, filtering supernatant, bottling and sterilizing. The precipitate produced in the high speed centrifugating is produced into pet food via compounding with flour and other material, sterilizing and pelletizing. The present invention has high material utilization and low production cost.
Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
This study has done at Mashhad Ghaem Educational center. Two nurses and an anesthesia resident selected and trained according to the latest guidelines of CPR . In the control sample, with the declare of code 99 and attend the team on the patient's bedside, CPR begins and then every two minutes, return of the patient checks in the usual way. quality performance of rescuers ,Recovery or death of the patient and the result is recording. In the second phase , group members were educated how to use capnography (Comdek's MD-660P Oxi-Capnography) in CPR and guiding restoration efforts by it. with the code 99 and attend the team on the patient's bedside capnography uses and its waveforms will appear on the monitor device which is visible to all rescuers and the quality of performance is renewed based on the its guidance. The two groups patients for age, sex, initial rhythm of arrest, time of arrest until the first action, the time of arrest until the first shocks are comparing to control these factors influence on the outcome. quality performance of rescuers , resuscitation outcomes and CPR duration and relative factors in each of the groups were recorded and compared.
PepT1, a proton-coupled oligopeptide transporter, is crucial for intestinal homeostasis. It is mainly expressed in small intestine enterocytes, facilitating the absorption of di/tri-peptides from dietary proteins. In the colon, PepT1 expression is minimal to prevent excessive responses to proinflammatory peptides from the gut microbiota. However, increased colonic PepT1 is linked to chronic inflammatory diseases and colitis-associated cancer. Despite promising results from animal studies on the benefits of extracellular vesicles (EVs) from beneficial gut commensals in treating IBD, applying probiotic EVs as a postbiotic strategy in humans requires a thorough understanding of their mechanisms. Here, we investigate the potential of EVs of the probiotic Nissle 1917 (EcN) and the commensal EcoR12 in preventing altered PepT1 expression under inflammatory conditions, using an interleukin (IL)-1-induced inflammation model in Caco-2 cells. The effects are evaluated by analyzing the expression of PepT1 (mRNA and protein) and miR-193a-3p and miR-92b, which regulate, respectively, PepT1 mRNA translation and degradation. The influence of microbiota EVs on PepT1 expression is also analyzed in the presence of bacterial peptides that are natural substrates of colonic PepT1 to clarify how the regulatory mechanisms function under both physiological and pathological conditions. The main finding is that EcN EVs significantly decreases PepT1 protein via upregulation of miR-193a-3p. Importantly, this regulatory effect is strain-specific and only activates in cells exposed to IL-1β, suggesting that EcN EVs does not control PepT1 expression under basal conditions but can play a pivotal role in response to inflammation as a stressor. By this mechanism, EcN EVs may reduce inflammation in response to microbiota in chronic intestinal disorders by limiting the uptake of bacterial proinflammatory peptides.
Disclosed are a nano-hydroxyapatite-based active calcium complex, a preparation method therefor and use thereof. The active calcium complex has a core-shell structure. The core comprises nano-hydroxyapatite, and the shell comprises, from the inside out, a calcium phosphate layer and a colloid layer. The characteristic that amorphous calcium phosphate silicate degrades to produce nano-hydroxyapatite is utilized to generate hydroxyapatite in vitro by means of water degradation. Co-precipitation and a gel method are used to form, on the surface of nano-hydroxyapatite, a calcium phosphate layer consisting of calcium hydrogen phosphate and tricalcium phosphate and a calcium silicate-containing colloidal layer formed from calcium silicate and silicic acid released by amorphous calcium phosphate silicate, sequentially. The colloidal layer serves to disperse the nano-hydroxyapatite coated with the calcium phosphate layer, preventing it from further agglomerating. In saliva, after the complex enters dental tubules, the colloid layer absorbs water and swells, rapidly blocking dental tubules; meanwhile, active calcium and a phosphorus source are assembled into hydroxyapatite, achieving a long-acting blocking effect on dental tubules and promoting enamel remineralization.
NEW MATERIAL:A selenium-containing compound shown by the formula I or formula II(A is group shown by the formula III, or formula IV; R<1> and R2 are aryl, or alkyl) or its salt. EXAMPLE:4-Methyl-3-phenylcarbamoyl-1,2,5-selenodiazole. USE:A low toxic carcinostatic agent having improved action on Ehrlich ascites carcinoma. PROCESS:A compound shown by the formula V is reacted with selenium dioxide preferably in the presence of a solvent such as dioxane, etc. to give a compound shown by the formula I or formula II. The reaction temperature is preferably 50 deg.C- the boiling point of the reaction mixture, and the reaction finishes usually about an hour.
Visual disorders are common even after mild traumatic brain injury (mTBI) or blast exposure. The cost of blast-induced vision loss in civilians, military personnel, and veterans is significant. The visual consequences of blasts associated with TBI are elusive. Active military personnel and veterans report various ocular pathologies including corneal disorders post-combat blasts. The wars and conflicts in Afghanistan, Iraq, Syria, and Ukraine have significantly increased the number of corneal and other ocular disorders among military personnel and veterans. Binocular vision, visual fields, and other visual functions could be impaired following blast-mediated TBI. Blast-associated injuries can cause visual disturbances, binocular system problems, and visual loss. About 25% of veterans exposed to blasts report corneal injury. Blast exposure induces corneal edema, corneal opacity, increased corneal thickness, damage of corneal epithelium, corneal abrasions, and stromal and endothelial abnormality including altered endothelial density, immune cell infiltration, corneal neovascularization, Descemet membrane rupture, and increased pain mediators in animal models and the blast-exposed military personnel including veterans. Immune response exacerbates blast-induced ocular injury. TBI is associated with dry eyes and pain in veterans. Subjects exposed to blasts that cause TBI should undergo immediate clinical visual and ocular examinations. Delayed visual care may lead to progressive vision loss, lengthening/impairing rehabilitation and ultimately may lead to permanent vision problems and blindness. Open-field blast exposure could induce corneal injuries and immune responses in the cornea. Further studies are warranted to understand corneal pathology after blast exposure. A review of current advancements in blast-induced corneal injury will help elucidate novel targets for potential therapeutic options. This review discusses the impact of blast exposure-associated corneal disorders.
L-arginine is an essential amino acid in pregnancy and a key mediator of placental development and function. In many low-resource settings, widespread protein undernutrition contributes to L-arginine deficiency in pregnancy which is associated with an increased risk of adverse pregnancy outcomes. Using a preclinical model, we have previously shown that dietary L-arginine supplementation enhances placental vascular development and improves pregnancy outcomes. L-citrulline is an amino acid that is efficiently converted to L-arginine in the body and has a more palatable flavour profile. The primary objective is to to determine if daily antenatal oral supplementation with L-citrulline can reduce adverse pregnancy outcomes (defined as a composite of fetal loss, infants born preterm, small for gestational age or with low birthweight) among pregnant women at high risk of malaria and protein undernutrition in Kenya.This is an individually randomized, two-arm, parallel-group, placebo-controlled clinical trial involving 2,960 pregnant women randomly assigned to one of two study arms. The intervention arm will contain L-citrulline arm -twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring (n=1,480); or placebo arm containing 6.0 g sachet of quality-assured placebo, each consisting of 3.6 g maltodextrin and 2.4 g lactose monohydrate, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring (n=1,480). All participants will continue to take the assigned product for 6 weeks after delivery and will receive an enhanced antenatal standard of care. The primary outcome is the clinical composite 'adverse pregnancy outcome'. Secondary outcomes include longitudinal assessments of physiological and molecular markers of endothelial function, angiogenesis, inflammation, placental function, L-arginine metabolism, neonatal sepsis, mortality, and early childhood neurocognitive development to age 24 months. The effect of L-citrulline supplementation on the composition of the participants' vaginal microbiota and the intestinal microbiota of both the participants and their newborns will be analysed in a subset of 132 mother/infant dyads. All maternal participants of the AGREE trial will be followed for 6 weeks post-partum and the children will be followed until age 2 years. Written informed consent will be obtained.
Fifty voluntary patients who underwent arthroscopic rotator cuff repair, aged between 35-64 years will be randomly divided into two groups: Cross-education group and standard rehabilitation group. Interventions will be applied for 16 sessions (twice a week for 8 weeks). The patients will be assessed at baseline, at the end of the 8-week intervention and 1-month follow-up. The pain on activity, at rest and at night will be assessed with Visual Analog Scale (VAS). Active range of motion will be assessed with a digital goniometer. Isometric muscle strength will be measured with a handheld dynamometer. The functional status will be evaluated by Constant-Murley Score (CMS) and American Shoulder and Elbow Surgeons (ASES) Score. Health-related quality of life will be assessed with Short Form-12 (SF-12). The Global Rating of Change will be used to evaluate patient satisfaction.
524,445. Lactoflavin and its phosphates. NAAMLOOZE VENNOOTSCHAP ORGANON. Jan. 27, 1939, No. 2889. Convention date, Jan. 28, 1938. [Class 2 (iii)] Lactoflavin and its phosphoric acid ester are separated by eluting an adsorbate containing both substances, such as the vitamin B2 complex, with an aqueous solution of an amine or amine salt or amide of 1-10 per cent. strength, the ester being washed out. Alternatively, the column may be divided into two sections when the adsorbed layers have become separated at different levels by the elution. In a modification, lactoflavin may be adsorbed from a solution of the mixture in a solution having the composition of the eluting agent described above, such as a 0.1-.5 per cent. pyridine solution, the ester being left unadsorbed. Suitable adsorbents are fuller's earth, china clay and the substance sold under the Registered Trade Mark "Floridin." Examples describe elution with aqueous pyridine, acetamide, and quinoline acetate respectively, and the absorption of lactoflavin in fuller's earth from a mixed aqueous solution containing 1 per cent. of pyridine..